Growth, Tolerance in Healthy Infants Fed a Partially Hydrolyzed Rice Protein
Rose
Phase 3 Safety Study of a Partially Hydrolyzed Rice Protein Formula in Healthy Infants
1 other identifier
interventional
86
1 country
9
Brief Summary
The purpose of this study is to assess growth and global tolerance in healthy new born infants with minor gastrointestinal troubles and/or allergic risk, fed an experimental partially hydrolyzed rice protein infant formula.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_3
Started Sep 2007
9 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2009
CompletedFirst Submitted
Initial submission to the registry
September 14, 2009
CompletedFirst Posted
Study publicly available on registry
October 20, 2009
CompletedOctober 20, 2009
October 1, 2009
1.9 years
September 14, 2009
October 19, 2009
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Growth parameters
2nd, 4th and 6th months
Secondary Outcomes (2)
Clinical Tolerance
3 days before the 2nd and 6th months
Atopic diseases (eczema atopic, asthma)
2nd and 6th months
Study Arms (1)
Modilac Rose 1
EXPERIMENTALInfant formula with partially hydrolysed rice protein
Interventions
Eligibility Criteria
You may qualify if:
- Term health infants with gestational age ranging from 37 to 42 weeks
- Infants less than 1 month old
- Growth parameter normal
- Apgar score \> 5 to 7 minutes
- Change in the formula because of digestive troubles (colics, gas, regurgitation) or risks of allergy
- Absence of metabolic, nervous or digestive troubles
- Absence of digestive haemorrhage, apnea or dizzy turn
You may not qualify if:
- Partial breastfed children
- Infants presenting a cow's milk protein allergy
- Infants currently participating in another trial
- Infants presenting an organic disease involving medicinal or surgical treatment
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sodilaclead
Study Sites (9)
Unknown Facility
Aix-les-Bains, 73100, France
Unknown Facility
Asnières, 92600, France
Unknown Facility
Besançon, 25000, France
Unknown Facility
Boulogne-Billancourt, 92100, France
Unknown Facility
Caen, 14000, France
Unknown Facility
Écully, 69130, France
Unknown Facility
Lyon, 69005, France
Unknown Facility
Meaux, 77100, France
Unknown Facility
Saint-Priest-en-Jarez, 42270, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jean-Philippe Girardet, PhD
Hôpital d'enfants Armand Trousseau
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
September 14, 2009
First Posted
October 20, 2009
Study Start
September 1, 2007
Primary Completion
August 1, 2009
Study Completion
August 1, 2009
Last Updated
October 20, 2009
Record last verified: 2009-10